Haemostasis Research Unit, Haematology Department, University College London, London, UK.
Dig Dis Sci. 2011 Aug;56(8):2456-65. doi: 10.1007/s10620-011-1729-4. Epub 2011 May 15.
ADAMTS13 deficiency leading to excess ultralarge von Willebrand factor (VWF) multimers and platelet clumping is typically found in thrombotic thrombocytopenic purpura (a type of thrombotic microangiopathy). Idiopathic noncirrhotic intrahepatic portal hypertension (NCIPH) is a microangiopathy of portal venules associated with significant thrombocytopenia and predisposing gut disorders.
To determine whether the portal microangiopathy in NCIPH is associated with ADAMTS13 deficiency.
Plasma levels of ADAMTS13, anti-ADAMTS13 antibodies, and VWF were compared between cases (NCIPH patients) and controls (with chronic liver diseases of other etiology) matched for severity of liver dysfunction. Eighteen NCIPH patients [median (range) MELD score 12 (7-25)] and 25 controls [MELD score 11 (4-26)] were studied.
ADAMTS13 activity was reduced in all 18 NCIPH patients and significantly lower than controls (median, IQR: 12.5%, 5-25% and 59.0%, 44-84%, respectively, P<0.0001) [normal range for plasma ADAMTS13 activity (55-160%)]. ADAMTS13 activity was <5% in 5/18 NCIPH patients (28%) and 0/25 controls (P=0.009). ADAMTS13 antigen levels were also decreased. Sustained low ADAMTS13 levels were seen in four NCIPH patients over 6 weeks to 11 months (highest ADAMTS13 level in each patient: <5%, 6%, 6%, and 25%), despite two patients having MELD score 12. Although nine cases had low titer anti-ADAMTS13 antibodies, there was no significant difference between cases and controls. Abnormally large VWF multimers were observed in 4/11 NCIPH patients (36%) and in 0/22 controls (P=0.008).
Sustained deficiency of ADAMTS13 appears characteristic of NCIPH, irrespective of severity of liver disease.
ADAMTS13 缺乏导致超大 von Willebrand 因子(VWF)多聚体和血小板聚集,通常见于血栓性血小板减少性紫癜(一种血栓性微血管病)。特发性非肝硬化性肝内门静脉高压症(NCIPH)是一种门静脉小静脉的微血管病,与显著血小板减少症和易患肠道疾病相关。
确定 NCIPH 中的门静脉微血管病是否与 ADAMTS13 缺乏有关。
比较病例组(NCIPH 患者)和对照组(其他病因慢性肝病)的血浆 ADAMTS13 水平、抗 ADAMTS13 抗体和 VWF,这些病例组和对照组按肝功能障碍严重程度进行匹配。研究了 18 名 NCIPH 患者[中位(范围)MELD 评分 12(7-25)]和 25 名对照组[MELD 评分 11(4-26)]。
所有 18 名 NCIPH 患者的 ADAMTS13 活性均降低,明显低于对照组(中位数,IQR:12.5%,5-25%和 59.0%,44-84%,分别,P<0.0001)[血浆 ADAMTS13 活性正常范围(55-160%)]。5/18 名 NCIPH 患者(28%)和 0/25 名对照组(P=0.009)的 ADAMTS13 活性<5%。ADAMTS13 抗原水平也降低。4 名 NCIPH 患者在 6 周至 11 个月(每位患者的最高 ADAMTS13 水平:<5%、6%、6%和 25%)中持续出现低 ADAMTS13 水平,尽管有 2 名患者的 MELD 评分均为 12。尽管 9 例患者的低滴度抗 ADAMTS13 抗体,但病例组与对照组之间无显著差异。11 名 NCIPH 患者中有 4 名(36%)和 22 名对照组中有 0 名(P=0.008)观察到异常大的 VWF 多聚体。
ADAMTS13 的持续缺乏似乎是 NCIPH 的特征,与肝病严重程度无关。